Evidence map›Paper›PMID 42699651›Full record

ArticleAI in neuroscience2026

Single cell transcriptomic analysis by deep learning identifies novel microglial transcription regulations in Alzheimer's Disease.

Maitry Ronakbhai Trivedi, Jay Shah, Yi Su, Eric M Reiman, Teresa Wu, Qi Wang

Abstract read
In one paragraph

Article in AI in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maitry Ronakbhai TrivediSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, 85287, USA.
Jay ShahSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, 85287, USA.
Yi SuASU-Mayo Center for Innovative Imaging, Tempe, AZ, 85287, USA.
Eric M ReimanBANNER Alzheimer's Institute, Phoenix, AZ, 85006, USA.
Teresa WuSchool of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ, 85287, USA.
Qi WangASU-BANNER Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, 85281, USA.

Funding

Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI HEATHER Allyson BIMONTE-NELSON · 2021 to 2026
$24.9M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Discovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4M
Genetic Epidemiology of Cognitive Decline in an Aging Population SampleR01AG030146 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI EVANS, DENIS A · 2007 to 2018
$6.2M
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesR01AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2009 to 2013
$4.1M
Deconstructing and modeling the single cell architecture of the Alzheimer brainRF1AG057473 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2017 to 2018
$4.0M
Exploring the Role of the Brain Transcriptome in Cognitive DeclineR01AG036836 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DE JAGER, PHILIP L · 2011 to 2014
$2.9M
NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG030146NIA NIH HHS R01 AG036042NIA NIH HHS R01 AG036836NIA NIH HHS R01 AG048015NIA NIH HHS R01 AG073424NIA NIH HHS R21 AG091567NIA NIH HHS RC2 AG036547NIA NIH HHS RF1 AG057473NIA NIH HHS T32 AG082658NIA NIH HHS U01 AG032984NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG046161NIA NIH HHS U01 AG061356
6 · The paper itself

Abstract

Artificial Intelligence (AI) has been increasingly applied to investigate genetic irregularities associated with Alzheimer's Disease (AD). However, its potential to uncover deeper, more detailed molecular and cellular mechanisms remains underexplored, primarily due to limitations in integrating large-scale data and capturing the complex, cell-type-specific dynamics involved in AD pathology. Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool in transcriptomics, offering high-resolution, cell-specific insights into complex biological systems. Despite this advancement, a significant gap remains in identifying both common and cell-type-specific transcriptomic signatures that define AD-related cellular and molecular processes. To address this, we propose a deep learning framework leveraging a Multi-Layer Perceptron (MLP) to classify AD versus control nuclei using scRNA-seq data from the Religious Orders Study/Memory and Aging Project (ROSMAP). We focus on microglial subclusters, particularly those representing homeostatic and activated states, to train the MLP model for optimal classification performance. We utilize the predicted embeddings from the MLP to model a disease progression trajectory for each of the datasets. Our model demonstrates strong performance in both classification and disease trajectory inference. To enhance interpretability, SHapley Additive exPlanations (SHAP) are applied to identify key AD-associated genes. Based on the most salient genes implicated in AD, we built transcription gene regulatory networks, revealing novel transcription factors and regulons for AD pathogenesis. These regulons highlight profound impacts of dysregulations of proteostasis, endoplasmic reticulum (ER) stress responses, and circadian rhythm on synaptic plasticity and neuronal survival in AD, offering a more holistic approach to drug target discovery compared to conventional single-target strategies, potentially leading to greater efficacy in slowing or reversing disease progression. This work demonstrates the transformative potential of AI in elucidating the molecular mechanisms of AD, offering improvements over traditional methods and uncovering novel insights into disease pathogenesis and potential therapeutic targets.

Identifiers

PMID42699651
PMCPMC13544018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.